Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.75 |
| ▸ | CLK2 | P49760 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | BMX | P51813 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1726330 | 0.90 | BTK (0.85) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL709434 | 0.86 | BTK (1.00) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL1725599 | 0.83 | BTK (0.80) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL708965 | 0.82 | BTK (1.00) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL1725678 | 0.82 | BTK (0.70) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL1725222 | 0.82 | BTK (1.00) | BTKCLK2 | |
| SCHEMBL12602983 | 0.81 | BTK (0.75) | BTKCLK2KDM4ERAB9A | |
| SCHEMBL13893968 | 0.80 | BTK (0.60) | BTKCLK2KDM4ERAB9A | |
| SCHEMBL13574781 | 0.80 | BTK (0.72) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL1725376 | 0.80 | BTK (0.86) | BTKCLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129845-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES (HK) | 2012-05-24 | — | — | US | claimed |
| US-8124604-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-02-28 | — | — | US | claimed |
| US-20110105479-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2011-05-05 | — | — | US | claimed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | claimed |
| US-8822457-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822457-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822457-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140194413-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ROCHE PALO ALTO LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194413-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ROCHE PALO ALTO LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194413-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ROCHE PALO ALTO LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-8618098-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120129845-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES (HK) | 2012-05-24 | — | — | US | disclosed |
| US-20110105479-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2011-05-05 | — | — | US | disclosed |
| US-7902194-B2 | Inhibitors of bruton's tyrosine kinase | Roche Palo Alto (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902194-B2 | Inhibitors of bruton's tyrosine kinase | Roche Palo Alto (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902194-B2 | Inhibitors of bruton's tyrosine kinase | Roche Palo Alto (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2009156284-A1 | NOVEL SUBSTITUTED PYRIDIN-2-ONES AND PYRIDAZIN-3-ONES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-30 | — | — | WO | disclosed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105479-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | BTK 1/4885CLK2 499/4885EGFR 729/4885 |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | BTK, LCK, SYK | BTK 1/4885CLK2 946/4885EGFR 1155/4885 |
| US-20120129845-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | BTK 1/4885CLK2 499/4885EGFR 729/4885 |
| US-20140194413-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | BTK 1/4885CLK2 499/4885EGFR 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.